Live
FierceBiotech'We need to put some bad ideas to bed': Inside Incubate's battles for biotech on Capitol HillFierceBiotechAfter local tumor approval, Novocure touts positive data in metastatic pancreatic cancerFierceBiotechOtsuka buys Transcend in $1.2B deal, nabbing MDMA analog for psychiatric conditionsFierceBiotechAstraZeneca’s in vivo CAR-T bet eradicates cancer in 3 of 5 patients, but death mars datasetFierceBiotechChutes & Ladders—Tang takes over Aurinia after FDA brouhahaThermo FisherThermo Fisher Scientific collaborates with SHL Medical and expands Ridgefield site - ROI-NJEndpoints NewsAnaptysBio spins out biotech operations; Affibody's data in hidradenitis suppurativaBioPharma DiveNovartis targets Xolair successor in buyout of startup ExcellergyEndpoints NewsFDA approves Rocket's gene therapy for ultra-rare immune diseaseIlluminaVanguard realigns reporting; subsidiaries to report separately (Illumina, ILMN) - Stock TitanEndpoints NewsFDA approves Novo Nordisk's once-weekly insulinBioWorldShanghai Institute of Materia Medica discloses new GLP-1R agonists
BioPharma Dive Mar 27, 2026

Novartis targets Xolair successor in buyout of startup Excellergy

Novartis targets Xolair successor in buyout of startup Excellergy

Original
Body unavailable. Use the original source.

Directory

59 All